Mitotic arrest of breast cancer MDA-MB-231 cells by a halogenated thieno[3,2-d]pyrimidine.

doi:10.1016/j.bmcl.2015.02.071

Paper

DOI: 10.1016/j.bmcl.2015.02.071

Mitotic arrest of breast cancer MDA-MB-231 cells by a halogenated thieno[3,2-d]pyrimidine.

Published Apr 15, 2015 · Christina R. Ross, Kartik W Temburnikar, G. M. Wilson

Bioorganic & medicinal chemistry letters

Q2 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Halogenated thieno[3,2-d]pyrimidines can modify the cytotoxic mechanism of breast cancer MDA-MB-231 cells, affecting cell cycle status and cytotoxicity in a cell type-specific manner.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Full text analysis coming soon...

References

DOI: 10.1016/j.bmc.2014.02.033

Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.

Halogenated thieno[3,2-d]pyrimidines show antiproliferative activity against various cancer cell lines and show selective activity against various fungi.

2014·33citations·Kartik W Temburnikar et al.·Bioorganic & medicinal chemistry

Bioorganic & medicinal chemistry

DOI: 10.1038/nchembio.1337

Metrics other than potency reveal systematic variation in responses to cancer drugs.

Other parameters than potency should be considered in analyzing cancer drug responses, as they reveal systematic variation in cell line and drug class responses.

2013·294citations·M. Fallahi-Sichani et al.·Nature chemical biology

Nature chemical biology

DOI: 10.1038/cddis.2012.148

Mitosis-targeted anti-cancer therapies: where they stand

Antimitotic therapies show promise in targeting cancer cells during mitosis, but overcoming the unpredictable human body's response remains a challenge for clinical success.

2012·277citations·K-S Chan et al.·Cell Death & Disease

Cell Death & Disease

DOI: 10.1021/jm3003747

Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.

Novel, potent, and selective PI3K inhibitors show potential for treating rheumatoid arthritis by targeting B cell activity and CYP3A4 time-dependent inhibition.

2012·62citations·B. Safina et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.1021/jm300016v

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

New aminopyrimidine-based B-Raf inhibitors with improved solubility and pharmacokinetic profiles show strong efficacy in a B-Raf(V600E) mutant mouse xenograft model.

2012·43citations·S. Mathieu et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

Citations

DOI: 10.3390/molecules26072031

Design, Synthesis and Anticancer Activity of New Polycyclic: Imidazole, Thiazine, Oxathiine, Pyrrolo-Quinoxaline and Thienotriazolopyrimidine Derivatives

New polycyclic aromatic compounds show significant anticancer activity against various human cancer cell lines.

2021·22citations·A. Abu‐Hashem et al.·Molecules

Molecules

DOI: 10.1016/j.bbadis.2019.04.015

H+-dependent inorganic phosphate transporter in breast cancer cells: Possible functions in the tumor microenvironment.

An H+-dependent inorganic phosphate transporter in breast cancer cells may provide an alternative pathway for phosphate uptake in the tumor microenvironment, potentially regulating energetically expensive tumor processes.

2019·21citations·M. A. Lacerda-Abreu et al.·Biochimica et biophysica acta. Molecular basis of disease

Biochimica et biophysica acta. Molecular basis of disease

DOI: 10.1371/journal.pone.0191270

Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231

Inorganic phosphate transport in breast cancer cells is modulated by sodium and intracellular sodium gradient, suggesting it as a potential target for therapy against tumor progression.

2018·22citations·T. Russo-Abrahão et al.·PLoS ONE

PLoS ONE

DOI: 10.1039/C7RA12912B

Current research on anti-breast cancer synthetic compounds

New anti-breast cancer compounds show promising properties, offering a potential solution for more effective and safer treatment, potentially reducing poor response to drug therapy.

2018·29citations·Jia Liu et al.·RSC Advances

RSC Advances

DOI: 10.1515/acph-2017-0039

Synthesis and evaluation of antitumor activity of new 4-substituted thieno[3,2-d]pyrimidine and thienotriazolopyrimidine derivatives

Most newly synthesized compounds show potent anticancer activity comparable to doxorubicin, including human breast adenocarcinoma.

2017·6citations·H. Hafez et al.·Acta Pharmaceutica

Acta Pharmaceutica